Edge Capital Group LLC Acquires 76 Shares of Stryker Co. (NYSE:SYK)

Edge Capital Group LLC lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 7.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,144 shares of the medical technology company’s stock after purchasing an additional 76 shares during the period. Edge Capital Group LLC’s holdings in Stryker were worth $412,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Assenagon Asset Management S.A. grew its stake in shares of Stryker by 15.6% during the third quarter. Assenagon Asset Management S.A. now owns 10,304 shares of the medical technology company’s stock valued at $3,722,000 after purchasing an additional 1,392 shares during the last quarter. Arkadios Wealth Advisors lifted its holdings in Stryker by 23.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 732 shares of the medical technology company’s stock worth $265,000 after buying an additional 137 shares in the last quarter. J.W. Cole Advisors Inc. boosted its position in Stryker by 23.4% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 3,932 shares of the medical technology company’s stock valued at $1,420,000 after buying an additional 746 shares during the last quarter. Welch Group LLC increased its stake in shares of Stryker by 7.2% in the 3rd quarter. Welch Group LLC now owns 19,105 shares of the medical technology company’s stock valued at $6,902,000 after buying an additional 1,284 shares during the period. Finally, Forbes J M & Co. LLP raised its position in shares of Stryker by 3.6% during the third quarter. Forbes J M & Co. LLP now owns 3,648 shares of the medical technology company’s stock worth $1,318,000 after acquiring an additional 127 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

Shares of SYK opened at $388.11 on Tuesday. The stock has a 50 day simple moving average of $378.38 and a 200 day simple moving average of $369.78. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm has a market capitalization of $148.09 billion, a PE ratio of 50.01, a P/E/G ratio of 2.93 and a beta of 0.96.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the firm earned $3.46 earnings per share. Sell-side analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is 43.30%.

Insider Transactions at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent research reports. UBS Group raised their price target on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. The Goldman Sachs Group lifted their price target on shares of Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research report on Thursday, January 30th. Wells Fargo & Company increased their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research note on Tuesday, February 18th. Finally, Barclays lifted their target price on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.